Press Releases

InVivo Therapeutics Announces Closing of $15.2 Million Public Offering, Including the Exercise of Underwriter’s Overallotment Option

Published: June 25, 2018

CAMBRIDGE, Mass. (June 25, 2018) – InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the closing of its public offering of 388,403 shares of its common stock, together with warrants to purchase 388,403 shares of common stock at a combined price to the public of $2.00 per share and warrant, as well as pre-funded warrants to purchase up to an aggregate of 6,242,811 shares of common stock together with warrants to purchase 6,242,811 shares of common stock, at a combined price to the public of $1.99 per pre-funded warrant and warrant.  In addition, the underwriter exercised its option to purchase […]

View Article
InVivo Therapeutics Announces Pricing of $13.2 Million Underwritten Public Offering

Published: June 21, 2018

InVivo Therapeutics Announces Pricing of $13.2 Million Underwritten Public Offering CAMBRIDGE, Mass. (June 21, 2018) – InVivo Therapeutics Holdings Corp. (NVIV) today announced the pricing of an underwritten public offering of 388,403 shares of its common stock, together with warrants to purchase 388,403 shares of common stock at a combined price to the public of $2.00 per share and warrant, as well as pre-funded warrants to purchase up to an aggregate of 6,242,811 shares of common stock together with warrants to purchase 6,242,811 shares of common stock, at a combined price to the public of $1.99 per pre-funded warrant and […]

View Article
InVivo Therapeutics Reports 2018 First Quarter Financial Results

Published: May 7, 2018

Progress Update on INSPIRE 2.0 Trial, Finance Officer Appointment CAMBRIDGE, Mass. (May 7, 2018) – InVivo Therapeutics Holdings Corp. (NVIV) today provided a business and clinical update and reported financial results for the quarter ended March 31, 2018. Richard Toselli, M.D., President and Chief Executive Officer of InVivo, commented, “InVivo gained significant momentum in the first quarter of 2018, and we look forward to building on our positive momentum throughout the rest of the year.  We remain focused on the development of our Neuro-Spinal Scaffold™ and continue to take steps to reduce our expenses and maximize shareholder value.  Key spend […]

View Article
InVivo Therapeutics Announces Presentation of Complete Six-Month Primary Endpoint Results from the INSPIRE Study of the Investigational Neuro-Spinal Scaffold™ in Acute Thoracic Complete Spinal Cord Injury

Published: May 2, 2018

– Findings Presented at the 2018 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting – CAMBRIDGE, Mass. (May 2, 2018) – InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the presentation of the complete six-month primary endpoint results from the company’s single-arm The INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) at a medical meeting. The presentation was given by Stuart Lee, M.D., Division of Neurosurgery, Vidant Health, at the 2018 AANS Meeting during the Plenary Session II on Tuesday, May […]

View Article
InVivo Therapeutics Provides Business Update

Published: April 9, 2018

Announces Reverse Stock Split and Key Cost-Saving Initiatives CAMBRIDGE, Mass. (April 9, 2018) – InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today provided a general business update.  The company is announcing a 1-for-25 reverse stock split of its common stock and a proportionate reduction in its authorized common stock. The company anticipates the reverse stock split will become effective at 5:00 p.m. Eastern Time on April 16, 2018, and shares of InVivo Therapeutics common stock will trade on a post-split basis under the Company’s existing trading symbol, “NVIV,” at the market open on April 17, 2018. The new CUSIP number for […]

View Article
InVivo Therapeutics Announces Contemporary Thoracic SCI Registry Study (the “CONTEMPO Registry Study”) Findings

Published: March 19, 2018

-Validates previously established Objective Performance Criterion (OPC) – CAMBRIDGE, Mass. (March 19, 2018) – InVivo Therapeutics Holdings Corp. (NVIV) today announced top-line findings from its CONTEMPO Registry Study, designed to provide comprehensive natural history benchmarks for Neuro-Spinal Scaffold™ clinical study results. The CONTEMPO study includes neurological recovery data from registries of spinal cord injury (SCI) patients with similar baseline characteristics to those in the INSPIRE study.  Specifically, only patients injured between 2006 and 2016 and meeting inclusion and exclusion criteria similar to those in INSPIRE were included.  Examples of such criteria include age (16-70 years), T2-T12 neurological level of injury (NLI), […]

View Article
InVivo Therapeutics Reports 2017 Year-end Financial Results

Published: March 12, 2018

CAMBRIDGE, Mass. (March 12, 2018) – InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the year ended December 31, 2017. Richard Toselli, M.D., President and Chief Executive Officer of InVivo, commented, “InVivo is charting a new and exciting path forward based on collaboration with the FDA that has continued through 2017 and into this year. We were pleased to announce last week that we received the agency’s approval of our supplemental Investigational Device Exemption (IDE) to initiate a second pivotal study of the company’s Neuro-Spinal Scaffold™ in patients with acute spinal cord injury (SCI). We believe this second […]

View Article
InVivo Therapeutics Receives FDA Approval for Pivotal, Randomized, Controlled Trial of the Neuro-Spinal Scaffold™ in Patients with Acute Spinal Cord Injury

Published: March 8, 2018

Study Designed to Enhance Clinical Evidence from INSPIRE Study and Support Potential Humanitarian Device Exemption (HDE) Submission CAMBRIDGE, Mass. (March 8, 2018) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company has received supplemental Investigational Device Exemption (IDE) approval from the US Food and Drug Administration (FDA) for a second pivotal clinical study of the company’s Neuro-Spinal Scaffold™ in patients with acute spinal cord injury (SCI). The 20-patient (10 subjects in each study arm), randomized, controlled trial is designed to enhance the existing clinical evidence for the Neuro-Spinal Scaffold™ from the company’s single-arm  INSPIRE study (InVivo Study of Probable Benefit […]

View Article
InVivo Therapeutics Announces Appointment of Richard Toselli, M.D., as President and Chief Executive Officer

Published: February 5, 2018

Dr. Toselli Also Joins Board of Directors, Retains Position as InVivo’s Chief Medical Officer CAMBRIDGE, Mass. (February 5, 2018) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Richard Toselli, M.D., has been appointed President and Chief Executive Officer of InVivo, having been appointed the company’s Acting CEO in December 2017. Dr. Toselli also has been appointed to the company’s Board of Directors and will continue to serve in his capacity as InVivo’s Chief Medical Officer, which role he assumed upon joining the company in July 2017. Dr. Toselli, a Board-certified neurosurgeon, has led an accomplished career in surgical medical […]

View Article
InVivo Therapeutics Announces Purchase Agreement for up to $15 Million with Lincoln Park Capital

Published: January 26, 2018

CAMBRIDGE, Mass. (Jan 26, 2018) – InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced that it has entered into a common stock purchase agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”), a Chicago-based institutional investor, under which the Company has the right to sell up to $15 million in shares of common stock to Lincoln Park over a twenty-four-month period, subject to certain limitations and conditions set forth in the purchase agreement and registration rights agreement, including: the company, in its sole discretion, controls the timing and amount of any sales of common stock; the purchase price is based on […]

View Article

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on the InVivo website for historical purposes only. InVivo assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.